Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott C Woller

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 15, 2015
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)Scott C Woller, Scott M Stevens, David A Kaplan, et al.
Journal of Cardiovascular Electrophysiology|August 14, 2015
Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of DementiaVictoria Jacobs, Scott C Woller, Scott M Stevens, et al.
American Heart Journal|June 5, 2017
Atrial fibrillation incrementally increases dementia risk across all CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc strata in patients receiving long-term warfarinKevin G Graves, Heidi T May, Victoria Jacobs, et al.
Chest|February 13, 2016
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel ReportClive Kearon, Elie A Akl, Joseph Ornelas, et al.
Journal of Thrombosis and Haemostasis : JTH|September 22, 2023
Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registryAndrea Lee Cervi, Darrin Applegate, Scott M Stevens, et al.
Lupus|October 26, 2020
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment TrendsHannah Cohen, Maria J Cuadrado, Doruk Erkan, et al.
Chest|August 5, 2021
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Chest|August 5, 2021
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Heart Rhythm|August 12, 2014
Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementiaVictoria Jacobs, Scott C Woller, Scott Stevens, et al.
Journal of the American College of Cardiology|November 3, 2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized TrialsCandrika D Khairani, Antoine Bejjani, Gregory Piazza, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 15, 2015
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)Scott C Woller, Scott M Stevens, David A Kaplan, et al.
Journal of Cardiovascular Electrophysiology|August 14, 2015
Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of DementiaVictoria Jacobs, Scott C Woller, Scott M Stevens, et al.
American Heart Journal|June 5, 2017
Atrial fibrillation incrementally increases dementia risk across all CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>VASc strata in patients receiving long-term warfarinKevin G Graves, Heidi T May, Victoria Jacobs, et al.
Chest|February 13, 2016
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel ReportClive Kearon, Elie A Akl, Joseph Ornelas, et al.
Journal of Thrombosis and Haemostasis : JTH|September 22, 2023
Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registryAndrea Lee Cervi, Darrin Applegate, Scott M Stevens, et al.
Lupus|October 26, 2020
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment TrendsHannah Cohen, Maria J Cuadrado, Doruk Erkan, et al.
Chest|August 5, 2021
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Chest|August 5, 2021
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Heart Rhythm|August 12, 2014
Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementiaVictoria Jacobs, Scott C Woller, Scott Stevens, et al.
Journal of the American College of Cardiology|November 3, 2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized TrialsCandrika D Khairani, Antoine Bejjani, Gregory Piazza, et al.
Pageof 9